No Data
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt
Lepu Biopharma Cancer Drug's NDA Approved by China's NDMA; Stocks Up 8%
Luoping Biosciences-B (02157.HK): MRG003 for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) has been accepted for new drug application by the National Medical Products Administration and included in priority review.
September 27, Geelonghui - The company LePu Biology-B (02157.HK) announced that it has received the "Acceptance Notice" issued by the China National Medical Products Administration (NMPA). The company's candidate drug MRG003 (an epidermal growth factor receptor (EGFR) targeted antibody-drug conjugate (ADC) candidate drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC))'s new drug application (NDA) has been accepted. MRG003 has also been included in the priority review by the NMPA Center for Drug Evaluation (CDE) ("Priority Review").
Luopu Biology-B (02157): NMPA accepted the drug registration application of MRG003 and included it in the priority review.
Lupe Bio-B (02157) announced that the company has received the issuance from the National Medical Products Administration (NMPA) of china...
Express News | Lepu Biopharma Co Ltd - Acceptance of New Drug Application and Priority- Review Granted by Nmpa to- Mrg003
LEPU BIO-B: 2024 Interim Report
No Data
No Data
